mercredi 17 octobre 2018

Onco Actu du 17 octobre 2018

4.12 Biopsies liquides

New blood test could spare cancer patients from needless chemotherapy after surgery [The Conversation]

4.2 Dép., diag. & prono. - Génome

The Results of Your Genetic Test Are Reassuring. But That Can Change. [NY Times]

Distinguishing Variant Pathogenicity From Genetic Diagnosis [JAMA]

5.1 Traitements - Pré-clinique

New study discovers inhibitors of protein linked to the devastating childhood brain cancer DIPG [Institute of Cancer Research]

CDER Scientists Investigate Critical Cellular Functions That Can Be Targeted to Kill Cancer Cells [FDA]

5.12 Immunothérapies

Replacing Antibodies With Small Molecules [In the Pipeline]

5.2.1 Pharma - Partenariats

Six years after a spectacular debut, Warp Drive Bio is powering down and handing its ‘undruggable’ ambitions over to Revolution [EndPoints]

5.2.3 Pharma - économie

Johnson & Johnson edges past profit estimates, lifts outlook [Reuters]

5.3 Traitements - FDA, EMA, NICE...

EU authorities take further action in ongoing review of sartans: Zheijiang Huahai placed under increased supervision; Aurobindo Pharma stopped from supplying irbesartan to the EU Share [EMA]

EU expands look at Zhejiang Huahai as impurities show up in other 'sartans' [FiercePharma]

5.3.4 Traitements - AMM (FDA, EMA,...)

FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer [FDA]

FDA approves Pfizer's drug for advanced breast cancer [Reuters]

5.4 Traitements - Economie

Guest column: The real cost of drug development [EndPoints]

6.11 Patients

The New Age of Patient Autonomy [JAMA]

6.7.1 IA/bioinformatique

M.I.T. Plans College for Artificial Intelligence, Backed by $1 Billion [NY Times]